CVS settles controlled-substance and false-claims allegations for $315 million plus interest
Oct 18, 2026 edition · GC-2026-0352 · Published 2026-10-18 · Version 1 · Settled
CVS executed settlements totaling $315 million in principal, plus interest on the civil settlement, without admitting liability. A related DEA agreement establishes controls for covered CVS retail pharmacies through August 15, 2032. Its operational requirements and implementation clock apply to CVS under the agreement.
What happened
DOJ announced October 13 that CVS Pharmacy Inc. and related entities settled allegations involving unlawful controlled-substance dispensing and federal healthcare claims for conduct from October 17, 2013 through December 2, 2025. The executed agreements, whose latest signatures are dated October 13, divide the $315 million principal into $126 million under the Controlled Substances Act and $189 million under the civil settlement. The latter adds annual interest of 3.63% from September 8, 2026 and designates $94.5 million as compensatory restitution. Both agreements expressly state that CVS denies the allegations, admits no liability and has not been found liable. DOJ alleged unresolved prescribing warning signs and linked dispensing failures to corporate performance metrics, staffing and restrictions on sharing prescriber concerns.
The attached DEA memorandum applies to CVS Pharmacy retail stores registered with DEA that fill prescriptions for its defined designated controlled substances; Caremark specialty and mail-order pharmacies are expressly outside its scope. Its implementation date is 30 days after full execution on October 13, and its term runs through August 15, 2032. Required controls include documenting resolution of identified prescription warning signs, protecting pharmacists' professional refusal decisions, reviewing unresolved prescriber concerns and blocking prescribers unless prohibited by federal or state law, proactive pharmacy reviews, an anonymous hotline, annual controlled-substance inventories and compliance reporting to DEA. These are CVS agreement requirements. They provide concrete control examples for other organizations without imposing the same agreement-specific reporting schedules or implementation dates across the industry.
Scope and timing
- Authority status
- Settled
- Applicability
- Operationally relevant
- Audience
- Health systems, Provider networks
- Jurisdiction
- Federal
Why it matters
The resolution connects controlled-substance dispensing, federal reimbursement and corporate operating practices. Its detailed safeguards illustrate how professional judgment, shared prescriber information, documented warning-sign resolution and monitoring can function together. The settlement's allocation, interest and CVS-specific scope must remain distinct from generally applicable law.
Recommended action
Assess whether staffing, productivity expectations, prescriber-alert sharing and documentation allow pharmacists to resolve controlled-substance concerns before dispensing and billing. Compare relevant controls with the executed memorandum while separately identifying the organization's own legal requirements. The playbook dates below are recommended internal review targets.
Case details
- agencies
- DOJ, DEA, HHS-OIG
- entities
- CVS Pharmacy Inc., Related CVS defendant entities
- action Type
- Settlement
- event Date
- 2026-10-13
- alleged Conduct
- Unlawful controlled-substance dispensing and federal reimbursement claims involving allegedly invalid prescriptions, unresolved warning signs and corporate operating practices.
- resolution
- Executed settlements require $126 million under the CSA and $189 million under the civil agreement, totaling $315 million principal. The civil amount accrues 3.63% annual interest from September 8, 2026 and includes $94.5 million compensatory restitution. CVS denies liability. A retail-pharmacy DEA memorandum begins 30 days after October 13 execution and runs through August 15, 2032.
Operational lessons
- Evaluate staffing and incentives alongside dispensing controls.
- Document resolution of identified prescription warning signs and preserve pharmacists' professional judgment.
- Connect prescriber concerns with enterprise review and dispensing-system controls.
- Distinguish settlement principal, interest and restitution allocations.
- Apply the memorandum's scope and deadlines to CVS rather than presenting them as industry-wide requirements.
Implementation playbook
- Recommended internal target: map controlled-substance escalation, staffing coverage, performance incentives and the ability to share prescriber concerns across locations. Compliance · Due 2026-10-23
- Recommended internal target: sample higher-risk dispensing patterns for documented warning-sign resolution and professional judgment; record remediation owners and distinguish internal recommendations from CVS-specific agreement terms. Clinical Operations · Due 2026-10-30
Sources
- DOJ announcement of CVS controlled-substance and false-claims settlementsOfficial · U.S. Department of Justice · 2026-10-13
- CVS Controlled Substances Act settlement and attached DEA memorandumOfficial · U.S. Department of Justice
- CVS civil settlement agreementOfficial · U.S. Department of Justice
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Enforcement Briefing report →